Management of acute attacks of hereditary angioedema: potential role of icatibant
Hilary J LonghurstDepartment of Immunology, Barts and The London NHS Trust, London, UKAbstract: Icatibant (Firazyr®) is a novel subcutaneous treatment recently licensed in the European Union for acute hereditary angioedema. Hereditary angioedema, resulting from inherited partial C1 inhib...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-09-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/management-of-acute-attacks-of-hereditary-angioedema-potential-role-of-a5217 |